Chapter 1 Executive Summary
1.1 Market Snapshot
Chapter 2 Research Methodology
2.1 Information Procurement
2.2 Information or Data Analysis
2.3 Market Formulation & Validation
Chapter 3 Market Variables, Trends, & Scope
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Rising pharma R&D outsourcing
3.1.1.2 Growing accessibility to Artificial Intelligence (AI) for pharmaceutical research
3.1.1.3 Expansion in the global drug developer in Asian market
3.1.2 Market restraint analysis
3.1.2.1 Different approval timelines
3.1.2.1 Presence of well-established players in western market
3.2 Penetration & Growth Prospect Mapping For Process Step Scope, 2018
3.3 Asia Pacific Drug Development Market-Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.4 Industry Analysis - Porter’s
Chapter 4 Asia Pacific Drug Development Market Categorization: Mode Estimates & Trend Analysis
4.1 Asia Pacific Drug Development Market: Mode Movement Analysis
4.2 In house
4.2.1 Asia pacific in house drug development market, 2015 - 2026 (USD Million)
4.3 Outsourced
4.3.1 Asia pacific outsourced drug development market, 2015 - 2026 (USD Million)
Chapter 5 Asia Pacific Drug Development Market Categorization: Process Step Estimates & Trend Analysis
5.1 Asia Pacific Drug Development Market: Process Step Movement Analysis
5.2 Process Research Development
5.2.1 Asia pacific drug development market for process research development, 2015 - 2026 (USD Million)
5.3 Formulation
5.3.1 Asia pacific drug development market for formulation step, 2015 - 2026 (USD Million)
5.4 Analytical & stability studies
5.4.1 Asia pacific drug development market for analytical & stability studies, 2015 - 2026 (USD Million)
5.5 Drug Metabolism and Pharmacokinetics (DMPK)
5.5.1 Asia pacific drug development market for Drug Metabolism and Pharmacokinetics (DMPK), 2015 - 2026 (USD Million)
5.6 Safety Assessment (Toxicology)
5.6.1 Asia pacific drug development market for safety assessment (Toxicology), 2015 - 2026 (USD Million)
5.7 Regulatory Compliance
5.7.1 Asia pacific drug development market for regulatory compliance, 2015 - 2026 (USD Million)
5.8 Packaging
5.8.1 Asia Pacific drug development market for packaging, 2015 - 2026 (USD Million)
Chapter 6 Asia Pacific Drug Development Market Categorization: Therapeutic Area Estimates & Trend Analysis
6.1 Asia Pacific Drug Development Market: Therapeutic Area Movement Analysis
6.2 Oncology
6.2.1 Asia Pacific drug development market for oncology, 2015 - 2026 (USD Million)
6.3 Inflammation & Immunology
6.3.1 Asia Pacific drug development market for inflammation & immunology, 2015 - 2026 (USD Million)
6.4 Cardiology
6.4.1 Asia Pacific drug development market for cardiology, 2015 - 2026 (USD Million)
6.5 Neuroscience
6.5.1 Asia Pacific drug development market for neuroscience, 2015 - 2026 (USD Million)
6.6 Others
6.6.1 Asia Pacific drug development market for other therapeutic area, 2015 - 2026 (USD Million)
Chapter 7 Asia Pacific Drug Development Market Categorization: Country Estimates & Trend Analysis, by Mode, Process Step, & Therapeutic Area
7.1 Asia Pacific Drug Development Market Share, By Country, 2018 & 2026
7.2 India
7.2.1 India drug development market, by mode, 2015 - 2026 (USD Million)
7.2.2 India drug development market, by process step, 2015 - 2026 (USD Million)
7.2.3 India drug development market, by therapeutic area, 2015 - 2026 (USD Million)
7.3 China
7.3.1 China drug development market, by mode, 2015 - 2026 (USD Million)
7.3.2 China drug development market, by process step, 2015 - 2026 (USD Million)
7.3.3 China drug development market, by therapeutic area, 2015 - 2026 (USD Million)
7.4 Singapore
7.4.1 Singapore drug development market, by mode, 2015 - 2026 (USD Million)
7.4.2 Singapore drug development market, by process step, 2015 - 2026 (USD Million)
7.4.3 Singapore drug development market, by therapeutic area, 2015 - 2026 (USD Million)
7.5 Japan
7.5.1 Japan drug development market, by mode, 2015 - 2026 (USD Million)
7.5.2 Japan drug development market, by process step, 2015 - 2026 (USD Million)
7.5.3 Japan drug development market, by therapeutic area, 2015 - 2026 (USD Million)
7.6 South Korea
7.6.1 South Korea drug development market, by mode, 2015 - 2026 (USD Million)
7.6.2 South Korea drug development market, by process step, 2015 - 2026 (USD Million)
7.6.3 South Korea drug development market, by therapeutic area, 2015 - 2026 (USD Million)
7.7 Indonesia
7.7.1 Indonesia drug development market, by mode, 2015 - 2026 (USD Million)
7.7.2 Indonesia drug development market, by process step, 2015 - 2026 (USD Million)
7.7.3 Indonesia drug development market, by therapeutic area, 2015 - 2026 (USD Million)
7.8 Australia
7.8.1 Australia drug development market, by mode, 2015 - 2026 (USD Million)
7.8.2 Australia drug development market, by process step, 2015 - 2026 (USD Million)
7.8.3 Australia drug development market, by therapeutic area, 2015 - 2026 (USD Million)
7.9 Malaysia
7.9.1 Malaysia drug development market, by mode, 2015 - 2026 (USD Million)
7.9.2 Malaysia drug development market, by process step, 2015 - 2026 (USD Million)
7.9.3 Malaysia drug development market, by therapeutic area, 2015 - 2026 (USD Million)
7.10 Vietnam
7.10.1 Vietnam drug development market, by mode, 2015 - 2026 (USD Million)
7.10.2 Vietnam drug development market, by process step, 2015 - 2026 (USD Million)
7.10.3 Vietnam drug development market, by therapeutic area, 2015 - 2026 (USD Million)
Chapter 8 Asia Pacific Drug Development Market: Competitive Landscape
8.1 Strategy Framework
8.2 Market Participant Categorization
8.3 Company Profiles
8.3.1 Samsung BioLogics
8.3.1.1 Company overview
8.3.1.2 Financial performance
8.3.1.3 Product benchmarking
8.3.1.4 Strategic initiatives
8.3.2 WuXi Biologics
8.3.2.1 Company overview
8.3.2.2 Financial performance
8.3.2.3 Product benchmarking
8.3.2.4 Strategic initiatives
8.3.3 Celltrion Inc.
8.3.3.1 Company overview
8.3.3.2 Financial performance
8.3.3.3 Product benchmarking
8.3.3.4 Strategic initiatives
8.3.4 PT Kalbe Farma Tbk
8.3.4.1 Company overview
8.3.4.2 Financial performance
8.3.4.3 Product benchmarking
8.3.4.4 Strategic initiatives
8.3.5 Eurofins Advinus
8.3.5.1 Company overview
8.3.5.2 Financial performance
8.3.5.3 Product benchmarking
8.3.5.4 Strategic initiatives
8.3.6 Covance Inc.
8.3.6.1 Company overview
8.3.6.2 Financial performance
8.3.6.3 Product benchmarking
8.3.6.4 Strategic initiatives
8.3.7 Celerion
8.3.7.1 Company overview
8.3.7.2 Financial performance
8.3.7.3 Product benchmarking
8.3.7.4 Strategic initiatives
8.3.8 Parexel International Corporation
8.3.8.1 Company overview
8.3.8.2 Financial performance
8.3.8.3 Product benchmarking
8.3.8.4 Strategic initiatives
8.3.9 GVK Biosciences Private Limited
8.3.9.1 Company overview
8.3.9.2 Financial performance
8.3.9.3 Product benchmarking
8.3.9.4 Strategic initiatives
8.3.10 Vifor Pharma Asia Pacific Pte. Ltd
8.3.10.1 Company overview
8.3.10.2 Financial performance
8.3.10.3 Financial performance
8.3.10.4 Product benchmarking